PDL BioPharma, Inc.
PDLI
PDLI was delisted on the 30th of December, 2020.
140 hedge funds and large institutions have $214M invested in PDL BioPharma, Inc. in 2019 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 37 increasing their positions, 59 reducing their positions, and 22 closing their positions.
306% more call options, than puts
Call options by funds: $191K | Put options by funds: $47K
5% less funds holding
Funds holding: 148 → 140 (-8)
32% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 22
35% less capital invested
Capital invested by funds: $332M → $214M (-$118M)
37% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 59
Top Buyers
| 1 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$3.46M |
| 2 |
Morgan Stanley
New York
|
+$3.2M |
| 3 |
CM
Crestline Management
Fort Worth,
Texas
|
+$1.94M |
| 4 |
State of New Jersey Common Pension Fund D
Trenton,
New Jersey
|
+$1.82M |
| 5 |
JP Morgan Chase
New York
|
+$1.69M |
Top Sellers
| 1 |
State Street
Boston,
Massachusetts
|
-$9.15M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$8.25M |
| 3 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$3.81M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$2.23M |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$1.7M |
PDLI Hedge Fund Activity: Q3 2019 in Review
140 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q3 2019, worth a combined $214M — down 35% from $332M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of PDLI and 15 opened new positions — a net loss of 7 holders — while 59 trimmed existing stakes and 37 added.
The largest buyer was Brandes Investment Partners, adding an estimated $3.46M. The largest seller was State Street, cutting an estimated $9.15M.
- 140 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q3 2019, down from 148 in Q2 2019.
- Funds reported $214M of PDL BioPharma, Inc. stock for Q3 2019, down 35% quarter-over-quarter.
- 15 funds opened new PDL BioPharma, Inc. positions in Q3 2019 and 22 closed out, a net change of -7 holders.
- The largest PDL BioPharma, Inc. buyer in Q3 2019 was Brandes Investment Partners, an estimated $3.46M added.
- The largest PDL BioPharma, Inc. seller in Q3 2019 was State Street, an estimated $9.15M sold.
Based on aggregated 13F filings for Q3 2019.